State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing a beneficial ownership position in Syndax Pharmaceuticals Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 4,653,172 shares of Syndax Pharmaceuticals common stock.
  • Percent of class: The reported position represents 5.2% of Syndax Pharmaceuticals' outstanding common stock.
  • Shared voting power: State Street disclosed shared voting power over 4,436,323 shares, with sole voting power of 0.
  • Shared dispositive power: The filing reports shared dispositive power over 4,653,172 shares, with sole dispositive power of 0.
  • Filing type: State Street is classified as a parent holding company (HC), with the position held through five named investment adviser subsidiaries.
  • Event date: The date of the event requiring this filing was September 30, 2026.

State Street's Schedule 13G Ownership Disclosure for Syndax Pharmaceuticals

State Street Corporation, organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership in Syndax Pharmaceuticals Inc. (CUSIP 87164F105), whose principal executive offices are located at 35 Gatehouse Drive, Building D, 3rd Floor, Waltham, Massachusetts 02451. The filing was signed by Alok Maheshwary, Senior Vice President, on November 9, 2026.

According to the filing, State Street beneficially owns 4,653,172 shares of Syndax Pharmaceuticals common stock, representing 5.2% of the class. The filing indicates that State Street holds 0 shares with sole voting power and 0 shares with sole dispositive power. Shared voting power covers 4,436,323 shares, while shared dispositive power covers all 4,653,172 shares reported as beneficially owned.

The filing identifies five subsidiaries through which the position is held: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. All five are classified as investment advisers (IA). State Street certified in the filing that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed, via Schedule 13G, beneficial ownership of 4,653,172 shares of Syndax Pharmaceuticals Inc. common stock, equal to 5.2% of the class, as of September 30, 2026, held through five investment adviser subsidiaries.